Abstract: To investigate the frequency and the spectrum of major opportunistic infections (OIs), evaluate the major clinical factors associated with each specific OI, and identify the risk factors for in-hospital death among HIV patients in East China.

A retrospective cohort study was made including all the HIV-infected patients who were admitted for the first time to the Shanghai Public Health Clinical Center during June 1, 2013 to June 1, 2015. The demographic and clinical data were collected. Comparison of continuous variables was analyzed by one-way ANOVA and rank sum test. Person χ² test and Fisher exact test were applied to analyze the categorical variables. A Cox proportional hazards regression model was used to determine the risk for the occurrence of in-hospital death.

In total, 920 patients were enrolled with age of 41.59 ± 13.36 years and 91% male. Median CD4 was 34 (IQR, 13–94) cells/µL. Among these patients, 94.7% acquired OIs while the rest developed malignancies. Pneumocystis pneumonia and bacterial coinfection (42.1%) was found to be the most common OIs, followed by tuberculosis (31.4%), Cryptococcosis (9.0%), and MAC infection (5.2%). Of the above 5 major OIs, CMV-infected patients had the lowest median CD4 cell count 12.50 (IQR, 7.50–50.00) in these patients. Of note, admitted patients with 2 types of OIs (2.20, 95% CI 1.39–3.48) and those patients who were 40-year old or older (1.75, 95% CI 1.10–2.78) had a higher risk of such death.

Pneumocystis pneumonia and tuberculosis were still the leading causes for the admission of HIV-infected patients in East China, and these patients tended to have very low CD4 cell counts. It is believed that expanding the HIV screening test and pushed the infected ones get ART earlier is required for generating a more successful HIV management strategy.

Abbreviations: ART = antiretroviral therapy, CMV = Cytomegalovirus, IQR = interquartile range, MAC = Mycobacterium avium complex, NFATP = National Free Antiretroviral Treatment Program, OIs = opportunistic infections, PCP = Pneumocystis pneumonia, PLWH = people living with HIV, TB = tuberculosis.

INTRODUCTION

According to the China Global AIDS Response Progress Report, 501,000 cases of people were reported to be living with HIV/AIDS by the end of 2014, of whom 205,000 were reported to be AIDS patients in China. Meanwhile, 159,000 deaths had been reported across the country.1 HIV infection destroys mainly the adaptive immune system, which makes the affected people highly susceptible to opportunistic infections (OIs) as well as AIDS-related malignancies. Global evidence has shown that OIs grossly affect the health and quality of life of HIV-infected people by causing higher morbidity and mortality among those individuals. Since combined antiretroviral therapy (cART) gradually restores the immune system, its widely use has been associated with a dramatic decreasing of the incidence of OIs in HIV-infected patients.2–4

However, AIDS-defining diseases, including OIs and malignancies, still pose a challenge to the healthcare system in China even if the Chinese government initiated the National Free Antiretroviral Treatment Program (NFATP) in 2003.5 On the one hand, considering it has been over 2 decades since the first case of HIV infection was found in 1985, an increase in the number of HIV-infected people with an advanced stage of disease is not unexpected. On the other hand, in a relative resource-limited country like China, there is no doubt that not every HIV-infected person is covered by the NFATP to receive ART before they are presenting to hospital with certain HIV-related clinical symptoms. What is more, some of the HIV-infected people always hesitate to receive the antiretroviral therapy after they were diagnosed. Consequently, most of them get admitted because of severe opportunistic infections.6

Several studies have described the spectrum of OIs in hospitalized HIV-infected patients in many countries, such as Gabon,7 South Africa,8 India,9 Thailand,10 Bangladesh,11 South Korea,12 and Japan.13 Unfortunately, data on the prevalence of various OIs and malignancies in admitted HIV-infected individuals in China is still lacking.14

Therefore, the purpose of this study is: to estimate the proportion of admissions attributable to specific OIs among people living with HIV (PLWH) and identify the most frequent...
ones, to characterize the major clinical factors associated with each specific OI, to determine the cumulative proportion of deaths that occur in hospital of admitted patients and identify risk factors for such mortality.

METHODS

Ethics Statement

This research protocol has been approved by the Shanghai Public Health Clinical Center Ethics Committee. Individual written informed consent was waived as the study was retrospective, anonymous and only used the currently existing data.

Study Design

This retrospective cohort study was conducted at the Shanghai Public Health Clinical Center, the largest referral center for patients with HIV infection or AIDS in East China. Eligible patients who were for their first time admitted to our center from June 1, 2013 to June 1, 2015 were selected. The inclusive criteria: with HIV antibody test positive (by western blot); with age more than 16-year old. The diagnosis of OIs and malignancies was taken in accordance with the guideline recommended by the United States Center for Disease Control and Prevention (CDC). CMV viremia was detected by PCR. Patients with other non-AIDS-related opportunistic infections and malignancies or with other internal diseases were excluded: drug-induced liver damage, drug-induced dermatitis, bone marrow suppression, and lactic acidosis (n = 85); other non-AIDS-related malignancies (n = 10); diabetes (n = 13); cardiovascular or cerebrovascular disease (n = 27); HIV/HBV, HIV/HCV or syphilis infection (n = 136); chronic kidney disease (n = 14); other Internal diseases (n = 177); central nervous system diseases (n = 37) (Figure 1). The demographic and clinical information including age, sex, duration of ART before admission, length of hospital stay, treatment outcomes, geographic distribution, and occupations and medical insurance were collected. CD4 levels and HIV viral load were measured within 1 week after admission.

Statistical Analysis

Entry and analysis of all data were conducted using IBM SPSS version 19.0 (IBM SPSS Inc, Armonk, NY). Mean (± standard deviation, SD) was used to describe continuous variables that meet the normal distribution, while percentage (%) was used for categorical variables. When statistical distribution was skewewed, data were expressed as median (interquartile range (IQR)). Comparison of continuous variables was analyzed by 1-way ANOVA or Kruskal–Wallis test or Mann–Whitney test. Person x^2 test and Fisher exact tests were

| FIGURE 1. Flow diagram of the study. |
| --- |

| TABLE 1. Clinical Characteristics of Selected Patients |
| --- |

| Patients | N = 920 |
| --- | --- |
| Age (mean ± SD, y) | 41.59 ± 13.36 |
| Male sex | 834 (90.7%) |
| Geographic distribution |  |
| Northeast China | 17 (1.8%) |
| Northwest China | 16 (1.7%) |
| Southwest China | 44 (4.8%) |
| East China | 800 (87.0%) |
| North China | 6 (0.7%) |
| Central China | 37 (4.0%) |
| CD4 median (IQR), cells/µL | 34.00 (13.00–94.00) |
| LOS median (IQR), d | 16.00 (9.00–26.00) |
| ART, mo |  |
| ≤ 6 | 821 (89%) |
| > 6 | 99 (11%) |

ART = antiretroviral therapy, LOS = length of hospital stay.
**TABLE 2. Prevalence of Opportunistic Infections and AIDS-Related Malignancies in 920 Patients**

| Diagnosis                        | Prevalence (%) |
|----------------------------------|----------------|
| PCP + bacterial coinfection      | 387 (42.1)     |
| Tuberculosis                     |                |
| Pulmonary tuberculosis          | 196 (21.3)     |
| Lymphoid tuberculosis           | 24 (2.6)       |
| Tuberculous meningitis          | 23 (2.5)       |
| Tuberculous pleuritis           | 17 (1.8)       |
| Intestinal tuberculosis         | 20 (2.2)       |
| Tuberculous pericarditis        | 3 (0.3)        |
| Tuberculous peritonitis         | 2 (0.2)        |
| Other extrapulmonary tuberculosis | 5 (0.5)     |
| Cryptococcosis                   |                |
| Cryptococcal meningitis         | 70 (7.6)       |
| Pulmonary Cryptococcosis        | 7 (0.8)        |
| Cryptococcal septicemia         | 4 (0.4)        |
| Cryptococcal antigenemia        | 2 (0.2)        |
| CMV infection                   |                |
| CMV retinitis                   | 42 (4.6)       |
| CMV viremia                     | 148 (16.1)     |
| CMV pneumonia                   | 1 (0.1)        |
| CMV colitis                     | 1 (0.1)        |
| MAC                              | 48 (5.2)       |
| Penicillium                     | 43 (4.7)       |
| Marnefetti                      |                |
| Herpes zoster                   | 33 (3.6)       |
| Cerebral                        | 17 (1.8)       |
| Toxoplasmosis                   |                |
| Kaposi Sarcoma                  | 16 (1.7)       |
| Lymphoma                        |                |
| Diffuse large B-cell lymphoma   | 12 (1.3)       |
| Unclassified lymphoma           | 10 (1.1)       |
| Bunkitt lymphoma                | 10 (1.1)       |
| Plasmablastic lymphoma          | 2 (0.2)        |
| PML                              | 4 (0.4)        |
| Other fungal infection           | 46 (5.0)       |

CMV = cytomegalovirus, MAC = mycobacterium avium complex, PCP = Pneumocystis pneumonia, PML = progressive multifocal leukoencephalopathy.

applied to analyze the categorical variables. A Cox proportional hazards regression analysis was made to determine the risk for the occurrence of in-hospital death. Factors significantly associated ($P < 0.10$) in univariate analysis were included in multivariate analysis. Statistical significance was determined using a conventional $P$ level of 0.05 (2-tailed). All of the clinical data underlying these findings are listed in the Supplementary Material File, http://links.lww.com/MD/A999.

**RESULTS**

**Characteristics of the Study Population**

In total, 1419 patients were admitted to the Department of Infectious Diseases of Shanghai Public Health Clinical Center from June 1, 2013 to June 1, 2015. A total of 920 patients, of whom 871 had OIs and 49 had HIV-related malignancies, were selected. The rest 499 patients with other clinical symptoms were excluded from this study (Figure 1).

Of the 920 patients whose medical records were analyzed, their clinical characteristics were summarized as shown in Table 1. These patients came from different provinces in China, with 800 (87.0%) being from East China, followed by 44 (4.8%), 37 (4.0%), 17 (1.8%), 16 (1.7%), and 6 (0.7%) of them from Southwest, Central, Northeast, Northwest, and North of China.

Eight hundred thirty-four (91%) were male, and the mean (± SD) age was 41.59 (± 13.36) years. The median (IQR) CD4 cell count, which was detected within 1 week after admission, was 34 (13–94) cells/µL, with 560 (60.9%) patients having a CD4 count less than 50 cells/µL, followed by 142 (15.4%), 114 (12.4%), 70 (7.6%), and 34 (3.7%) of the patients having a CD4 count of 51 to 100, 101 to 200, 201 to 350, and more than 350 cells/µL, respectively. Six hundred sixty-nine (72.7%) patients paid to take a HIV viral load test on admission. The HIV-RNA median log10 copies/mL of these patients was 5.35 (IQR, 4.97–5.70). Of note, 821 (89%) patients had received ART for no more than 6 months before presenting to our hospital, including 666 patients who were treatment naive. Among the 254 patients (27.6%) who had received ART before admission, 222 (24.1%) were on a regimen with 2 types of nucleoside reverse transcriptase inhibitors (NRTIs) and 1 type of non-nucleoside reverse transcriptase inhibitors (NNRTI), 30 (3.3%) were with 2 types of NRTIs and 1 type of protease inhibitors (PIs), 1 (0.1%) was with 2 types of NNRTIs and 1 type of integrase inhibitors (INIs), and another was with 1 NRTI + 1 NNRTI + 1 PI. The median (IQR) length of stay in the hospital was 16.00 (9.00 – 26.00) days.

**Prevalence of Major OIs and Its Related Factors**

Of the total 920 clinical records analyzed, 871 (94.7%) had opportunistic infections (OIs), and only 49 (5.3%) had AIDS-related malignancies (Table 2). Among the patients who acquired OIs, 845 patients received anti-infection treatment before ART initiation, while AIDS-related OIs newly occurred in 75 patients who were on ART. The most common OIs were Pneumocystis pneumonia (PCP) and bacterial co-infection, and the prevalence was 42.1%. This was followed by tuberculosis (31.4%). CMV was the third most frequent OIs and developed in 20.9% of patients: retinitis, 42 patients; viremia, 148 patients; pneumonia, 1 patient; and colitis, 1 patient. The frequencies of other OIs among 920 patients are: Cryptococcosis (83 patients, 9.0%), Toxoplasmosis (73 patients, 8.0%), CMV (44 patients, 4.8%), 37 (4.0%), 17 (1.8%), 16 (1.7%), and 6 (0.7%) of them from Southwest, Central, Northeast, Northwest, and North of China.
| Total Patients (n = 581) | PCP+Bacterial Infections (n = 263) | Pulmonary Tuberculosis (n = 144) | Extrapulmonary Tuberculosis (n = 51) | Cryptococcosis (n = 59) | MAC (n = 32) | CMV (n = 32) | P Value |
|-------------------------|-------------------------------------|----------------------------------|-------------------------------------|------------------------|--------------|-------------|---------|
| Age median (IQR)        | 39.00 (31.00–52.00)                | 42.00 (30.00–53.00)             | 40.00 (30.00–49.00)                 | 36.00 (30.00–44.00)   | 37.00 (32.00–48.00) | 35.50 (31.00–43.75) | 0.114   |
| Sex                     |                                    |                                  |                                     |                        |              |             | 0.814   |
| Male                    | 529 (91.0)                         | 242 (92.0)                      | 128 (88.9)                         | 45 (88.2)              | 55 (93.2)    | 30 (93.8)   |         |
| Geographic distribution  |                                    |                                  |                                     |                        |              |             | 0.498   |
| Northeast China         | 11 (1.9)                           | 6 (2.3)                         | 0 (0.0)                            | 3 (5.9)                | 2 (3.4)      | 0 (0.0)     | 0 (0.0)  |
| Northwest China         | 10 (1.7)                           | 1 (0.4)                         | 5 (3.5)                            | 2 (3.9)                | 1 (1.7)      | 1 (3.1)     | 0 (0.0)  |
| Southwest China         | 28 (4.8)                           | 11 (4.2)                        | 8 (5.6)                            | 1 (2.0)                | 4 (6.8)      | 3 (9.4)     | 1 (3.1)  |
| East China              | 505 (86.9)                         | 230 (87.5)                      | 125 (86.8)                         | 44 (86.3)              | 50 (84.7)    | 27 (84.4)   | 29 (90.6) |
| North China             | 4 (0.7)                            | 2 (0.8)                         | 1 (0.7)                            | 0 (0.0)                | 1 (1.7)      | 0 (0.0)     | 0 (0.0)  |
| Central China           | 23 (4.0)                           | 13 (4.9)                        | 5 (3.5)                            | 1 (2.0)                | 1 (1.7)      | 1 (3.1)     | 2 (6.3)  |
| CD4 median (IQR)        | 38.00 (16.00–102.50)               | 32.00 (14.00–67.00)             | 59.50 (27.50–175.25)               | 79.00 (24.00–179.00)  | 29.00 (11.00–89.00) | 40.50 (7.25–131.75) |              |
| LOS median (IQR)        | 15.00 (9.00–24.00)                 | 15.00 (9.00–21.00)              | 13.00 (8.00–22.00)                 | 13.00 (8.00–21.00)     | 13.00 (3.00–55.00) | 22.50 (9.00–41.75) |              |
| ART, mo                 |                                    |                                  |                                     |                        |              |             | 0.000   |
| ≤6                      | 511 (88.0)                         | 255 (97.0)                      | 120 (83.3)                         | 38 (74.5)              | 49 (83.1)    | 18 (56.3)   | 31 (96.9) |
| >6                      | 70 (12.0)                          | 8 (3.0)                         | 24 (16.7)                          | 13 (25.5)              | 10 (16.9)    | 14 (43.8)   | 1 (3.1)  |
| Outcome                 |                                    |                                  |                                     |                        |              |             | 0.700   |
| Deaths                  | 37 (6.4)                           | 19 (7.2)                        | 8 (5.6)                            | 3 (5.9)                | 5 (8.5)      | 0 (0.0)     | 2 (6.3)  |
| Nondeath                | 544 (93.6)                         | 244 (92.8)                      | 136 (94.4)                         | 48 (94.1)              | 54 (91.5)    | 32 (100)    | 30 (93.8) |

Age (years); CD4 (cells/μL).
ART = antiretroviral therapy, LOS = length of hospital stay (days).

*Patients with coinfections were excluded.*
etiologic groups with different infections, CMV-infected patients had the lowest median CD4 cell count 22.50 (IQR, 7.50–82.00) while the patients with tuberculosis (TB) infection had the highest CD4 cell count 61.00 (IQR, 27.00–176.00). Notably, the group of people with PCP plus bacterial infections had the highest in-hospital mortality rate (7.2%), while the 32 patients infected by MAC were all survived after treatment.

### Risk Factors for Hospital Death in HIV-Infected Patients

Among 920 patients who admitted due to OIs and AIDS-defining malignancies, 78 patients (8.5%) died while being treated in our hospital. The underlying causes of death of patients before being discharged are depicted in Figure 2. Of note, nearly half of the patients died in hospital due to other coinfections (47.4%). The second most prevalent in-hospital mortality cause was PCP and bacterial coinfections, followed by Mycobacterium Tuberculosis, Cryptococcosis, Lymphoma, CMV infection, and Penicillium Marneffei infection.

In the univariate analysis, the mean age (±SD) is significantly higher in the group of patients who died in hospital (47.38 ± 13.66 vs. 41.01 ± 13.30, \( P < 0.001 \)). The median CD4 cell count was significantly lower in the group of patients who died on admission (19.50 vs. 36.00, \( P < 0.01 \)). There was no significant difference between the duration of ART before hospitalization of the 2 groups (\( P = 0.20 \)) (Table 4). In addition, the distribution of various types of AIDS-related diseases (OIs and cancers) was also not significantly different between the patients who died or survived in our hospital (\( P = 0.95 \)). However, according to the results from multivariate Cox regression analysis, neither the CD4 cell count (\( P < 0.16 \)) nor the ART duration before admission (\( P < 0.16 \)) nor the ART duration before admission (\( P = 0.633 \)) was the risk factor for inhospital death. Interestingly, patients who were 40-year old or older had almost a 2-fold (AHR = 1.746; 95% CI, 1.097–2.777) higher risk of mortality while still being hospitalized compared with those less than 40-year old. Likewise, admitted patients with 2 types of OIs were about 2 times (AHR = 2.199; 95% CI, 1.389–3.480). (Table 5).

### FIGURE 2. Incidence of in-hospital death caused by specific type of opportunistic infections.

### TABLE 4. Univariate Predictors of In-Hospital Death in HIV-Infected Patients

|                       | Dead     | Survived | \( P \) Value |
|-----------------------|----------|----------|--------------|
| Age (mean ± SD)       | 47.38 ± 13.66 | 41.01 ± 13.30 | 0.000\(^*\) |
| Male sex              | 70       | 764      | 0.773\(^1\)   |
| Female sex            | 8        | 78       | 0.147\(^1\)   |
| Geographic distribution|          |          |              |
| Northeast China       | 3        | 14       |              |
| Northwest China       | 1        | 15       |              |
| Southwest China       | 2        | 42       |              |
| East China            | 66       | 734      |              |
| North China           | 2        | 4        |              |
| Central China         | 4        | 33       |              |
| CD4 median (IQR)      | 19.50 (6.00–49.50) | 36.00 (13.00–99.25) | 0.004\(^\dagger\) |
| LOS median (IQR)      | 13.50 (7.75–26.25) | 16.00 (9.00–26.00) | 0.264\(^\dagger\) |
| ART, mo               |          |          |              |
| \( \leq 6 \)          | 73       | 748      |              |
| >6                    | 5        | 94       |              |
| PCP+bacterial infections | 19      | 244      | 0.950\(^1\) |
| Pulmonary tuberculosis | 8        | 136      |              |
| Extrapulmonary tuberculosis | 3       | 48       |              |
| Cryptococcosis        | 5        | 54       |              |
| CMV                   | 2        | 30       |              |
| HIV-associated malignancies | 3   | 32       |              |

Age (years); CD4(cells/μL). ART = antiretroviral therapy, LOS = length of hospital stay (days). HIV-associated malignancies: Kaposi Sarcoma and Lymphoma.

\(^*\)One-way ANOVA.

\(^\dagger\)by Mann-Whitney test.

\(^1\)χ\(^2\) or Fisher exact test.
**DISCUSSION**

Despite the implementation of NFATP for more than 1 decade,\textsuperscript{5,14,16} the number of hospitalized HIV-infected patients due to OIs is still high. In China, OIs as well as HIV-related malignancies were treated in referral HIV/AIDS centers of tertiary care hospitals mainly located in big cities of each province. Therefore, a systemic evaluation of the nationwide prevalence and spectrum of OIs and HIV-related cancers in Chinese HIV-positive individuals is still lacking due to limited access to diagnostic and surveillance data. A recent retrospective observational study was conducted in Ditan hospital,\textsuperscript{14} but the spectrum of OIs and malignancies reported mainly applies to the North China.

In this study, the frequency and types of major OIs and malignancies in HIV-infected patients hospitalized at Shanghai Public Health Clinical Center were assessed. This hospital is the major center for HIV/AIDS diagnosis and treatment for people living in the East coastal area of China. Consistently, 800 of the 920 enrolled patients (87\%) came from the East China. Hence, the results generated from this study could neither represent the whole patients nor be applied to other regions of China.

As a result, 94.7\% of the patients acquired OIs, and only 5.3\% of them developed AIDS-related malignancies. Notably, 91\% of the affected patients were male, which is consistent with the findings in Ditan hospital of China (82.8\%), India (91.2\%), and Iran.\textsuperscript{13,17,18} In addition, the (mean ± SD) age of the affected patients was (41.59 ± 13.36) years, which indicates HIV-related diseases occurred more in the economically productive age group. This will probably increase the economic burden of their family and also our country.

Bacterial pneumonia and PCP coinfection was the most prevalent OIs in HIV patients in our study, as shown in other HIV-transmission categories,\textsuperscript{19} and followed by tuberculosis. Considering many studies in resource-limiting areas all observed that tuberculosis was the commonest OIs, our finding was unanticipated. One reason for this incompatible observation we made is because there actually is no consensus on the diagnostic criteria for PCP.\textsuperscript{20} Although an elevated serum level of lactate dehydrogenase (LDH) or S-adenosylmethionine (SAM) has been suggested as surrogate markers for PCP, these clinical findings are not specific enough to distinguish PCP from other types of pneumonia.\textsuperscript{21,22} Another reason is that the patients with PCP had a very low CD4 level when admitted, so it was very likely that these patients had an additional bacterial infection.

Tuberculosis was the second most prevalent OIs in HIV-infected patients in this study, and the prevalence was 31.4\%. This observation matches with many other findings.\textsuperscript{9,12,14,18,23–25} However, the frequencies of other major OIs were somewhat different. Previous studies that were conducted in Ditan hospital of China and in developed countries have shown that MAC infection was the common OI.\textsuperscript{14} In contrast, a relative low prevalence of MAC infection was observed in our study.

In this study, we did not list the diagnosis of Candidiasis because this kind of fungi infection is prevalent among HIV-infected patients in advanced stage, especially when their CD4 cell count is less than 50 cells/\mu L.\textsuperscript{26,27} However, most of our patients with this kind of infection receive treatment in the clinic but only a few patients get admitted.

The overall in-hospital mortality rate was 4.2 per 100 person-years, and the patients presented with other coinfections

**TABLE 5.** Risk Factors for In-Hospital Death Among HIV Patients at Shanghai Public Health Clinical Center, Shanghai, China, 2013–2015

| Variables          | Crude HR (95\% CI) | P Value | Adjusted HR (95\% CI) | P Value |
|--------------------|--------------------|---------|-----------------------|---------|
| Age, y             |                    |         |                       |         |
| <40 [Reference]    | 1.834 (1.155–2.913) | 0.010   | 1.746 (1.097–2.777)   | 0.019   |
| ≥ 40               |                     |         |                       |         |
| Sex                |                    |         |                       |         |
| Male (%) [Reference]| 1.307 (0.628–2.722) | 0.474   |                       |         |
| Female (%)         |                    |         |                       |         |
| Types of OIs       |                    |         |                       |         |
| One [Reference]    | 2.327 (1.475–3.672) | <0.0001 | 2.199 (1.389–3.480)   | 0.001   |
| Two                | 3.328 (1.022–10.84) | 0.046   | 2.899 (0.880–9.545)   | 0.080   |
| Three or more      | 3.328 (0.930–2.617) | 0.092   | 1.457 (0.866–2.451)   | 0.156   |
| CD4 distribution (%)|                    |         |                       |         |
| CD4 ≤ 50 cells/\mu L| 1.560 (0.930–2.617) | 0.092   | 1.457 (0.866–2.451)   | 0.156   |
| > 50 cells/\mu L [Reference]|             |         |                       |         |
| ART (mo) (%)       |                    |         |                       |         |
| <6 [Reference]     | 1.247 (0.503–3.089) | 0.633   |                       |         |
| ≥ 6                |                     |         |                       |         |
| Occupation         |                    |         |                       |         |
| Student            | 1.975 (0.473–8.242) | 0.351   |                       |         |
| Retired            | 2.054 (1.101–3.830) | 0.024   |                       |         |
| Unemployed         | 0.853 (0.516–1.413) | 0.537   |                       |         |
| Other [Reference]  |                    |         |                       |         |
| Medical insurance  |                    |         |                       |         |
| Yes                | 1.301 (0.830–2.038) | 0.251   |                       |         |
| No [Reference]     |                    |         |                       |         |
had the highest mortality rate (47.4%). Notably, none of the 32 hospitalized patients with MAC infection died before being discharged from our hospital. More importantly, we found that patients with age ≥40-year old, or with 2 types of OIs were at higher risk for death in hospital. Unexpectedly, CD4 cell counts <50 cells/μL (AHR of 1.457, 95% CI, 0.866–2.451, \( P = 0.16 \)) was not a risk factor for predicting in-hospital death. It is consistent with another study in Botswana which also showed that there was no correlation between lower CD4 + T-cell count and early mortality after ART. This phenomenon may also be explained by the endowed limitations in the present study. First, this is a retrospective study that is simply based on the data deposited in a tertiary referral HIV/AIDS care center, so the observations made in this study are undoubtedly somewhat biased. Second, almost all of the patients had a very low CD4 cell count on admission, so it is not impossible that certain number of patients have died before arriving at the hospital. Last but not least, the endpoint of study is restricted to the in-hospital period, which means the full access to patients’ follow-up clinical data after being discharged would not always be available.

In conclusion, PCP and TB were still the leading causes for the admission of HIV-infected patients in East China, and these patients tended to have very low CD4 cell counts. Being diagnosed and initiating ART timely should shrink the number of patients have died before arriving at the hospital. Last but not least, the endpoint of study is restricted to the in-hospital period, which means the full access to patients’ follow-up clinical data after being discharged would not always be available.

ACKNOWLEDGMENTS

We thank the entire medical staff of the Department of Infectious Diseases at Shanghai Public Health Clinical Center for their dedication and hard work. We also thank Dr Shuye Zhang for critical reading of the entire manuscript and providing valuable suggestions.

REFERENCES

1. National Health and Family Planning Commission. China Global AIDS Response Progress Report, 2015. Available at: http://www.aidsdatahub.org/china-global-aids-response-progress-report-2015-national-health-and-family-planning-commission-2015. Accessed December 9, 2015.
2. Croda J, Croda MG, Neves A, et al. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med. 2009;37:1605–1611.
3. Huang L, Quartin A, Jones D, et al. Intensive care of patients with HIV infection. N Engl J Med. 2006;355:173–181.
4. Casalino E, Wolff M, Ravaud P, et al. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS. 2004;18:1429–1433.
5. Zhang F, Haberer JE, Wang Y, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS. 2007;21: S143–148.
6. Zheng H, Wang L, Huang P, et al. Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study. BMC Public Health. 2014;14:381.
7. Okome-Nkoumou M, Guiedy V, Ondouna M, et al. Opportunistic diseases in HIV-infected patients in Gabon following the administration of highly active antiretroviral therapy: a retrospective study. Am J Trop Med Hyg. 2014;90:211–215.
8. Fenner L, Reid SE, Fox MP, et al. Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. Trop Med Int Health. 2013;18:194–198.
9. Saha K, Firdaus R, Santra P, et al. Recent pattern of co-infection amongst HIV seropositive individuals in tertiary care hospital, Kolkata. Virol J. 2011;8:116.
10. Puthanakit T, Auripobil L, Oderbroder P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599–604.
11. Shahrin L, Leung DT, Matin N, et al. Characteristics and predictors of death among hospitalized HIV-infected patients in a low HIV prevalence country: Bangladesh. PLoS One. 2014;9:e113095.
12. Oh MD, Park SW, Kim HB, et al. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis. 1999;29:1524–1528.
13. Katano H, Hishima T, Mochizuki M, et al. The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan. BMC Infect Dis. 2014;14:229.
14. Xiao J, Gao G, Li Y, et al. Spectrums of opportunistic infections and malignancies in HIV-infected patients in tertiary hospital care, China. PLoS One. 2013;8:e75915.
15. Siberry GK, Abzug MJ, Nachman S, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J. 2013;32:i–KK4.
16. Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China. J Acquir Immune Defic Syndr. 2013;63:e150–e157.
17. Ghate M, Deshpande S, Tripathy S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13:e1–e8.
18. Hajjabolbaghi M, Jafari S, Mansouri S, et al. Hospitalizations and its related factors in HIV/AIDS patients in Tehran, Iran. Med J Islam Repub Iran. 2014;28:70.
19. Feldman C, Anderson R. HIV-associated bacterial pneumonia. Clin Chest Med. 2013;34:205–216.
20. Huang L, Brothers K. HIV-associated opportunistic pneumonias. Respir Med. 2009;14:474–485.
21. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest. 1995;108:415–418.
22. Skelly M, Hoffman J, Fabbri M, et al. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet. 2003;361:1267–1268.
23. Damtse D, Yismaw G, Woldeyoannes D, et al. Common opportunistic infections and their CD4 cell correlates among HIV-infected patients attending at antiretroviral therapy clinic of Gondar University Hospital, Northwest Ethiopia. BMC Res Notes. 2013;6:534.
24. Sun HY, Chen MY, Hsieh SM, et al. Changes in the clinical spectrum of opportunistic illnesses in persons with HIV infection in Taiwan in the era of highly active antiretroviral therapy. Jpn J Infect Dis. 2006;59:311–316.
25. Mituku H, Weldgebebral F, Teklemariam Z. Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia. HIV AIDS (Auckl). 2015;7:137–144.
26. Barr CE. Oral diseases in HIV-1 infection. *Dysphagia*. 1992;7:126–137.

27. Kwamin F, Nartey NO, Codjoe FS, et al. Distribution of Candida species among HIV-positive patients with oropharyngeal candidiasis in Accra, Ghana. *J Infect Dev Ctries*. 2013;7:41–45.

28. Ravimohan S, Tamuha N, Steenhoff AP, et al. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis. *J Infect Dis*. 2013;208:1784–1793.